NCT00086216View on ClinicalTrials.gov

Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2004

Study Completion Date

November 30, 2007

Conditions
Multiple Myeloma
Interventions
DRUG

Atiprimod

Oral, once a day, 14 days on 14 days off

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Callisto Pharmaceuticals

INDUSTRY